Company intelligence / Profile preview

Brand Acumen

Charlottesville, Virginia, United Statesbrand-acumen-studios.com ↗

Ownership: Private
Employees: ~52
Development stage: Other

Overview

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for neurodegenerative diseases, with a primary focus on Alzheimer's disease. Its lead clinical candidate, sabirnetug (ACU193), is a monoclonal antibody specifically designed to target toxic soluble amyloid beta oligomers, currently in Phase 1 development for early Alzheimer’s disease.

Therapeutic areas: Neurology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Lonza (manufacturing collaboration)Merz Pharmaceuticals GmbHMerck Sharp & Dohme Corp.

Beyond the preview

Go deeper on Brand Acumen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brand Acumen.

Explore the full profile